文献速递心力衰竭与心肌病

FGF1纳米脂质体联合超声靶向微泡爆破治疗大鼠糖尿病心肌病

[Therapeutic effect of combined use of FGF1-loaded nano-liposomes and ultrasound-targeted microbubble destruction technique on treating rats with experimental diabetic cardiomyopathy].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2017-01-01

该研究在链脲佐菌素诱导的糖尿病心肌病大鼠模型中,比较生理盐水、FGF1溶液、FGF1纳米脂质体及FGF1纳米脂质体联合UTMD的疗效;联合组心功能、心肌胶原容积分数、微血管密度及凋亡指数均优于其他DCM组(P均<0.05)。

要点

  • FGF1纳米脂质体包封率为(84.3±2.8)%,形态与稳定性良好。
  • 联合UTMD组LVESP、LV±dp/dtmax高于其他DCM组,LVEDP低于其他DCM组(P均<0.05)。
  • 联合UTMD组CVF与凋亡指数低于、MVD高于其他DCM组(P均<0.05)。

核心结论

  • FGF1纳米脂质体结合UTMD可改善DCM大鼠心功能、减轻心肌胶原容积分数与凋亡、提高心肌微血管密度。

研究设计与样本

  • 健康雄性SD大鼠75只,随机选15只为正常对照组,其余腹腔注射链脲佐菌素(70 mg/kg)建立糖尿病模型,成模后饲养16周经超声心动图筛选DCM大鼠。
  • DCM大鼠随机分为DCM组、FGF1溶液组、FGF1纳米脂质体组和FGF1纳米脂质体+UTMD组,每组15只。
  • 采用水包水型乳化法结合冷冻干燥技术制备FGF1载药纳米脂质体;药物干预2周再继续饲养2周后行心导管及心肌组织学检测。

主要发现

  • 扫描电镜显示空白及载药纳米脂质体呈标准椭球形、分散均匀,FGF1包封率为(84.3±2.8)%。
  • FGF1纳米脂质体+UTMD组LVESP、LV+dp/dtmax和LV-dp/dtmax均显著高于DCM组、FGF1溶液组和FGF1纳米脂质体组(P均<0.05)。
  • FGF1纳米脂质体+UTMD组LVEDP显著低于DCM组、FGF1溶液组和FGF1纳米脂质体组(P均<0.05)。
  • DCM组心肌CVF明显大于对照组(P<0.05);FGF1溶液组、FGF1纳米脂质体组和FGF1纳米脂质体+UTMD组CVF均明显小于DCM组(P均<0.05),联合组进一步小于FGF1溶液组和FGF1纳米脂质体组(P均<0.05)。
  • DCM组MVD明显低于对照组(P<0.05);三个治疗组MVD均明显高于DCM组(P均<0.05),联合组明显高于FGF1溶液组和FGF1纳米脂质体组(P均<0.05);DCM组凋亡指数明显高于对照组(P<0.05),三个治疗组均明显低于DCM组(P均<0.05),联合组进一步低于FGF1溶液组和FGF1纳米脂质体组(P均<0.05)。

关键数值与推荐

  • FGF1载药纳米脂质体包封率为(84.3±2.8)%。
  • 糖尿病模型建立:腹腔注射链脲佐菌素70 mg/kg。
  • DCM大鼠随机分为4组,每组15只;药物干预2周再继续饲养2周。

临床怎么用

  • 原文结论为FGF1纳米脂质体结合UTMD可有效改善DCM大鼠心功能和心肌结构,有望成为治疗DCM的一种新方法。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: The therapeutic effect of acid fibroblast growth factor 1(FGF1) on rats with diabetic cardiomyopathy (DCM) was evaluated by using nano-liposomes combined with ultrasound-targeted microbubble destruction technique (UTMD). Methods: The FGF1-loaded nano-liposomes were prepared by water-in-water emulsion method combined with lyophilization technique.TypeⅠdiabetes model was induced by intraperitoneal injection of streptozotocin (STZ, 70 mg/kg) in 60 male SD rats.Sixteen weeks later, diabetic rats were randomly divided into: placebo group (saline treatment), FGF1 group, FGF1-loaded nano-liposomes group, and FGF1-loaded nano-liposomes plus UTMD group (n=15 each). After two weeks of intervention followed by 2 weeks intervention stop, all rats underwent cardiac catheterization, and the left ventricular end-systolic pressure (LVESP), left ventricular end-diastolic pressure (LVEDP) and the maximal increase/decrease rate of left ventricular pressure (LV±dp/dtmax) were measured.Then, the rats were sacrificed and myocardial tissue were obtained for Masson trichrome staining, TUNEL apoptotic staining and CD31 immunohistochemistry staining to quantify myocardial collagen fraction (CVF), cardiac myocyte apoptotic index and myocardial microvascular density (MVD). Results: (1)Scanning electron microscope results revealed good morphology and FGF1 encapsulation efficiency (84.3±2.8)% with high stability and dispensability of FGF1 loaded nano-liposomes.(2)The hemodynamic evaluation showed that LVESP, LV + dp/dt(max) and LV -dp/dt(max) were all significantly higher, while LVEDP was significantly lower in the FGF1-loaded nano-liposome+ UTMD group than in DCM group, FGF1 solution group, and FGF1 nano-liposome group(all P<0.05). (3)The Masson trichrome staining demonstrated that CVF was significantly higher in all DCM groups than in control group and was significantly lower in the FGF1-loaded nano-liposome+ UTMD group than in DCM group, FGF1 solution group, and FGF1 nano-liposome group (all P<0.05). (4)The CD31 immunohistochemical staining results showed that MVD was significantly lower in all DCM groups than in control group and was significantly higher in the FGF1-loaded nano-liposome+ UTMD group than in DCM group, FGF1 solution group, and FGF1 nano-liposome group (all P<0.05). (5)The TUNEL results showed that apoptotic index was significantly higher in all DCM groups than in control group and was significantly lower in the FGF1-loaded nano-liposome + UTMD group than in DCM group, FGF1 solution group, and FGF1 nano-liposome group (all P<0.05). Conclusion: FGF1 nano-liposomes combining with UTMD technique can significantly improve cardiac functions and attenuate myocardial CVF and apoptosis and enhance myocardial MVD in DCM rats. 目的: 研究酸性成纤维细胞生长因子1(FGF1)纳米脂质体结合超声靶向微泡爆破技术(UTMD)对于糖尿病心肌病(DCM)的治疗效果。 方法: 健康雄性Sprague Dawley大鼠75只,随机数字表法选择15只作为正常对照组(对照组),其余大鼠腹腔注射链脲佐菌素(70 mg/kg)建立糖尿病模型,成模后继续饲养16周,通过超声心动图筛选出DCM大鼠模型。将DCM大鼠按随机数字表法分为4组,即DCM模型组(DCM组,给予生理盐水治疗)、FGF1溶液治疗组(FGF1溶液组)、FGF1纳米脂质体治疗组(FGF1纳米脂质体组)和FGF1纳米脂质体+UTMD治疗组(FGF1纳米脂质体+UTMD组),每组15只。采用水包水型乳化法结合冷冻干燥技术制备FGF1载药纳米脂质体。药物干预2周再继续饲养2周后,采用心导管评价各组大鼠心功能。处死大鼠后取出心肌组织,分别通过Masson胶原染色、TUNEL凋亡染色及CD31免疫组织化学染色测定各组大鼠心肌胶原容积分数(CVF)、心肌凋亡指数及心肌微血管密度(MVD)。 结果: (1)FGF1纳米脂质体质量评价结果:扫描电镜观察空白及载药纳米脂质体均呈标准的椭球形,分散均匀且包封率高稳定性好。(2)各组大鼠心功能的心导管检测结果:FGF1纳米脂质体+UTMD组大鼠左心室收缩末期压力、左心室内压最大上升和下降速率均明显高于DCM组、FGF1溶液组和FGF1纳米脂质体组(P均<0.05),而左心室舒张末期压力则明显低于DCM组、FGF1溶液组和FGF1纳米脂质体组(P均<0.05)。(3)各组大鼠心肌CVF的测定结果:DCM组大鼠心肌CVF明显大于对照组(P<0.05)。FGF1溶液组、FGF1纳米脂质体组和FGF1纳米脂质体+UTMD组大鼠心肌CVF均明显小于DCM组(P均<0.05)。而FGF1纳米脂质体+UTMD组大鼠心肌CVF则进一步小于FGF1溶液组和FGF1纳米脂质体组(P均<0.05)。(4)各组大鼠心肌组织MVD的检测结果:DCM组大鼠心肌组织MVD明显低于对照组(P<0.05)。FGF1溶液组、FGF1纳米脂质体组和FGF1纳米脂质体+UTMD组大鼠心肌组织MVD均明显高于DCM组(P均<0.05)。FGF1纳米脂质体+UTMD组大鼠心肌组织MVD则明显高于FGF1溶液组和FGF1纳米脂质体组(P均<0.05)。(5)各组大鼠心肌细胞凋亡情况的检测结果:DCM组大鼠心肌细胞凋亡指数明显高于对照组(P<0.05)。FGF1溶液组、FGF1纳米脂质体组和FGF1纳米脂质体+UTMD组大鼠心肌细胞凋亡指数均明显低于DCM组(P均<0.05)。而FGF1纳米脂质体+UTMD组大鼠心肌细胞凋亡指数则进一步低于FGF1溶液组和FGF1纳米脂质体组(P均<0.05)。 结论: FGF1纳米脂质体结合UTMD可有效改善DCM大鼠心功能和心肌结构,有望成为治疗DCM的一种新方法。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang M, Zhao YZ, Ma WC, et al. [Therapeutic effect of combined use of FGF1-loaded nano-liposomes and ultrasound-targeted microbubble destruction technique on treating rats with experimental diabetic cardiomyopathy]. Zhonghua Xin Xue Guan Bing Za Zhi. 2017. PMID: 28511329. doi:10.3760/cma.j.issn.0253-3758.2017.05.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。